Ezscan: A new non-invasive technology to evidence cardiac autonomic neuropathy in diabetes / 中华内分泌代谢杂志
Xiaolin CAI; Zhihong YANG; Zhaoyun ZHANG; Renming HU.
Chinese Journal of Endocrinology and Metabolism
; (12): 631-633, 2011.
Artículo
en Zh
| WPRIM | ID: wpr-424266
Objective To assess the efficacy of Ezscan in evaluating the risk of cardiac autonomic neuropathy (CAN) in diabetes. Methods This study included 144 patients with diabetes. Their serum lipid profile and HbA1c were determined. The heart rate variability was assessed by Holter, and the cardiac autonomic neuropathy by classic experiments. Meanwhile, Ezscan was carried out. Results There was a positive correlation between low frequency (LF) measurements by Holter and Ezscan score( r=0. 39, P＜0. 01 ), so did LF/HF and Ezscan score( r=0. 28, P＜0. 01 ). Correlations between Ezscan score and other Holter parameters were weaker. There was no correlation between HbA1c and LF measurements. In patients with positive classic experiments, the sensitivity and specificity of Ezscan were 58. 3% and 57.8% respectively. Conclusions Ezscan test is a valuable screening procedure for detecting diabetic complications. It is more facilitative and takes shorter time than does the classical autonomic function assessment.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados